Access Bio, Inc.
65 Clyde Road, Suite A,
08873
Somerset, NJ
USA
USA
This company is co-exhibitor of
MEDISENSOR, INC.
Location
Hall map
Fairground map
Our range of products
Product categories
- 03 Diagnostic Tests
- 03.01 Clinical chemistry
- 03.01.04 Rapid tests in clinical chemistry
Rapid tests in clinical chemistry
Our products
Product category: Rapid tests in clinical chemistry
CareStart™ G6PD RDT*
Specifications
Test Type
Qualitative point-of-care test
Assay Method
Visual dye colorization method
Interpretation
Normal vs. deficient
Specimen
Whole blood
Specimen Volume
2 ㎕
Result Time
10 minutes
Package Size
25 or 50 tests/box
Other Specifications
CE Marked, Simple and easy to use, Broad range of assay temperature(18~32℃), Room temperature storage
G6PD deficiency
G6PD deficiency is a genetic disorder, resulting in no or low G6PD activity. People with G6PD deficiency should not take primaquine, an antimalarial drug, and other drugs with high oxidative stress because it could cause serious side effects such as acute hemolysis.
Features & Benefits
True Point-Of-Care Test for G6PD with >95% Sensitivity * for WHO classification Ⅰ&Ⅱ (<10% of normal activity)
CareStart™ G6PD RDT is a visual screening test that identifies G6PD deficient patients using whole blood sample.
Test Type
Qualitative point-of-care test
Assay Method
Visual dye colorization method
Interpretation
Normal vs. deficient
Specimen
Whole blood
Specimen Volume
2 ㎕
Result Time
10 minutes
Package Size
25 or 50 tests/box
Other Specifications
CE Marked, Simple and easy to use, Broad range of assay temperature(18~32℃), Room temperature storage
G6PD deficiency
G6PD deficiency is a genetic disorder, resulting in no or low G6PD activity. People with G6PD deficiency should not take primaquine, an antimalarial drug, and other drugs with high oxidative stress because it could cause serious side effects such as acute hemolysis.
Features & Benefits
True Point-Of-Care Test for G6PD with >95% Sensitivity * for WHO classification Ⅰ&Ⅱ (<10% of normal activity)
CareStart™ G6PD RDT is a visual screening test that identifies G6PD deficient patients using whole blood sample.
About us
Company details
Global Leading Bio Company, Access BioAccess Bio is dedicated to the prevention and early diagnosis of infectious diseases through research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. Particularly, early and accurate diagnosis is a key to effective treatment of patients. Our core in vitrodiagnostic technology includes immunochemical, biochemical and molecular products. Access Bio strives to establish a foundation for wellbeing of all people.
Access Bio tries to meet the market demands for accurate and cost-effective in vitro diagnosis at a whole new level of technology and product development. At Access Bio, our motto is “Sustainable Business by Affordable Products for Our Customers.” With this in mind, we try to serve our customers every corner of the world.
Access Bio tries to meet the market demands for accurate and cost-effective in vitro diagnosis at a whole new level of technology and product development. At Access Bio, our motto is “Sustainable Business by Affordable Products for Our Customers.” With this in mind, we try to serve our customers every corner of the world.